[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fN-W6R_Og4gW-aC9KXDlIYzrGA-MclKQzjg3-X8eCJ0U":3},{"answer":4,"createTime":5,"id":6,"options":7,"origin":13,"question":17,"related":18,"source":29,"type":81},[],"2026-05-13 19:03:35",1118877391,[8,9,10,11,12],"研究者应在24小时内向申办者报告该严重不良事件","申办者需按照ICH E2A要求向监管机构提交快速报告","申办者应暂停所有受试者的试验用药并终止试验","申办者需评估该事件对药品安全性的影响并更新风险控制计划","申办者应在下次PSUR中汇总分析该事件而不需单独报告",{"courseId":14,"workId":15,"workName":16},"1000151151","66976283","第四章单元测试","某临床试验中受试者出现严重肝功能损害,申办者应采取哪些符合药物警戒法规的措施",[19,31,39,48,53,62,71,82,92,95],{"answer":20,"createTime":21,"id":22,"options":23,"question":28,"source":29,"type":30},[],"2026-05-13 19:03:34",1118877286,[24,25,26,27],"药品生产阶段","药品运输阶段","药品销售阶段","药品临床试验阶段","药品上市前药物警戒主要关注的是哪个阶段药品的安全性","v2",0,{"answer":32,"createTime":21,"id":33,"options":34,"question":37,"source":29,"type":38},[],1118877293,[35,36],"对","错","药品上市前药物警戒是指在药品获得上市许可之后所开展的一系列监测、评估和管理活动",3,{"answer":40,"createTime":5,"id":41,"options":42,"question":47,"source":29,"type":30},[],1118877302,[43,44,45,46],"立即停止给药并记录不良反应的发生时间和症状","等待更多数据后再决定是否报告","仅向申办者口头报告不良反应情况","调整试验方案而不需要立即报告","在临床试验阶段发现严重不良反应后,研究人员首先应该采取的措施是什么",{"answer":49,"createTime":5,"id":50,"options":51,"question":52,"source":29,"type":38},[],1118877366,[35,36],"ICH E2C(R2)指南要求申办者在新药临床试验的早期阶段每6个月提交一次定期安全性更新报告(PSUR),随着临床试验的进展和数据的积累,提交频率可以逐渐降低",{"answer":54,"createTime":5,"id":55,"options":56,"question":61,"source":29,"type":30},[],1118877374,[57,58,59,60],"立即终止整个临床试验","24小时内将该事件报告给研究者,并在规定时间内向监管机构提交快速报告","等待收集更多病例后再进行评估","仅记录在案,待临床试验结束后统一报告","在临床试验中,发现某受试者出现严重肝功能损害.根据ICH E2A和《药物临床试验质量管理规范》,申办者应采取的首要措施是什么",{"answer":63,"createTime":5,"id":64,"options":65,"question":70,"source":29,"type":30},[],1118877379,[66,67,68,69],"对药品的背景信息进行全面调研","制定详细的临床试验方案","向药品监管部门提交临床试验申请","撰写安全性总结报告","在药品上市前药物警戒管理中,以下哪个环节不属于临床试验前的准备工作",{"answer":72,"createTime":5,"id":73,"options":74,"question":80,"source":29,"type":81},[],1118877380,[75,76,77,78,79],"临床试验前的准备工作包括制定详细的临床试验方案和提交IND申请","在临床试验阶段发现严重不良反应时应在24小时内向监管部门报告","临床试验后只需分析药物的疗效数据即可提交上市申请","药品上市前药物警戒管理的目的是确保药品上市后的安全有效使用","风险评估时若药物风险超过预期可考虑暂停或终止试验","以下关于药品上市前药物警戒管理实践流程的说法中,哪些是正确的",1,{"answer":83,"createTime":5,"id":84,"options":85,"question":91,"source":29,"type":81},[],1118877388,[86,87,88,89,90],"药物警戒学仅关注药品上市后的安全性监测","药物警戒学的主要目标是发现、评估和预防与药物相关的不良反应","药品上市前药物警戒管理的主要任务是识别和评估药物的安全性特征","药物警戒学不涉及药品质量的监测和管理","药物警戒学在药品临床试验期间就开始发挥重要作用","药物警戒学是药品研发和临床应用中的重要环节,下列哪些是关于药物警戒学正确的描述",{"answer":93,"createTime":5,"id":6,"options":94,"question":17,"source":29,"type":81},[],[8,9,10,11,12],{"answer":96,"createTime":5,"id":97,"options":98,"question":103,"source":29,"type":30},[],1118877399,[99,100,101,102],"仅关注药品上市后的不良反应监测","发现、评估、理解和预防与药物相关的问题","只研究药物在动物实验中的安全性","专注于药物的生产工艺优化","药物警戒学的主要研究内容是什么"]